MariMed (MRMD) AI Stock Analysis

Company Guidance

Management guided that the company will build on a record Q2 — consolidated revenue of $41.9M (≈+6% sequential, ≈+6% YoY) with adjusted EBITDA of $3.9M (≈+10% sequential; margin ≈9.4% vs 9.1% in Q1 and 12.1% a year ago) and GAAP net loss of $3.6M (improving from $3.8M); cash was $8.4M with $33.6M in operating working capital. They expect to continue the "Expand the Brand" strategy — investing in product innovation, broader state depth and capital‑light entry (brand licensing) — while keeping operating expense discipline ($15.2M, ≈36% of revenue) and targeting margin expansion as cultivation utilization improves and newer operations scale. Operationally they pointed to wholesale strength (wholesale ≈44% of product revenue; wholesale +6% sequential and ≈+8% YoY), a branded portfolio growing 70 basis points faster than the industry, distribution up 100 basis points to 85% of available storefronts, and retail momentum (retail +7% sequential, ≈+4% YoY; transactions +7% sequential; Thrive Perks membership +14% YTD; sequential revenue growth in 12 of 13 dispensaries and transaction growth in 10 of 13). Near‑term openings and milestones include Thrive Columbus contributing revenue later this year and a planned New York entry in H1 2027, with management anticipating incremental federal policy clarity (rescheduling/280E/banking) by year‑end.